FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
+6.79%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$180M
AUM Growth
+$180M
(-11%)
Cap. Flow
-$1.35M
Cap. Flow
% of AUM
-0.75%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
1
Closed
–
Top Buys
No buys this quarter
Top Sells
| 1 |
Lyell Immunopharma
LYEL
|
$1.35M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pharvaris
PHVS
$1.39B
| $78.1M | 43.39% | 3,743,450 | – | – |
|
|
CBAY
2
DELISTED
Cymabay Therapeutics
CBAY
| $26.6M | 14.8% | 1,787,094 | – | – |
|
3
Aclaris Therapeutics
ACRS
$209M
| $19.2M | 10.68% | 2,808,034 | – | – |
|
4
Kura Oncology
KURA
$686M
| $16.9M | 9.37% | 1,849,947 | – | – |
|
|
KNTE
5
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $13.5M | 7.52% | 9,671,643 | – | – |
|
|
6
Lyell Immunopharma
LYEL
$213M
| $12.9M | 7.17% | 8,784,813 -915,187 | -9% | -$1.35M |
|
7
Syndax Pharmaceuticals
SNDX
$1.41B
| $12.7M | 7.06% | 875,000 | – | – |
|